Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative
Dara Kusic,
Jessica Heil,
Stefan Zajic,
Andrew Brangan,
Oluseun Dairo,
Gretchen Smith,
Diego Morales-Scheihing,
Russell J. Buono,
Thomas N. Ferraro,
Rachel Haroz,
Matthew Salzman,
Kaitlan Baston,
Elliot Bodofsky,
Michael Sabia,
Alissa Resch,
Laura B. Scheinfeldt
Affiliations
Dara Kusic
Coriell Institute for Medical Research, Camden, NJ 08103, USA
Jessica Heil
Coriell Institute for Medical Research, Camden, NJ 08103, USA
Stefan Zajic
Coriell Institute for Medical Research, Camden, NJ 08103, USA
Andrew Brangan
Coriell Institute for Medical Research, Camden, NJ 08103, USA
Oluseun Dairo
Coriell Institute for Medical Research, Camden, NJ 08103, USA
Gretchen Smith
Coriell Institute for Medical Research, Camden, NJ 08103, USA
Diego Morales-Scheihing
Coriell Institute for Medical Research, Camden, NJ 08103, USA
Russell J. Buono
Cooper Medical School of Rowan University, Camden, NJ 08103, USA
Thomas N. Ferraro
Cooper Medical School of Rowan University, Camden, NJ 08103, USA
Rachel Haroz
Cooper University Health Care, Camden, NJ 08103, USA
Matthew Salzman
Cooper University Health Care, Camden, NJ 08103, USA
Kaitlan Baston
Cooper University Health Care, Camden, NJ 08103, USA
Elliot Bodofsky
Cooper University Health Care, Camden, NJ 08103, USA
Michael Sabia
Cooper University Health Care, Camden, NJ 08103, USA
Alissa Resch
Coriell Institute for Medical Research, Camden, NJ 08103, USA
Laura B. Scheinfeldt
Coriell Institute for Medical Research, Camden, NJ 08103, USA
Pharmacogenetics (PGx) has the potential to improve opioid medication management. Here, we present patient perception data, pharmacogenetic data and medication management trends in patients with chronic pain (arm 1) and opioid use disorder (arm 2) treated at Cooper University Health Care in Camden City, NJ. Our results demonstrate that the majority of patients in both arms of the study (55% and 65%, respectively) are open to pharmacogenetic testing, and most (66% and 69%, respectively) believe that genetic testing has the potential to improve their medical care. Our results further support the potential for CYP2D6 PGx testing to inform chronic pain medication management for poor metabolizers (PMs) and ultrarapid metabolizers (UMs). Future efforts to implement PGx testing in chronic pain management, however, must address patient concerns about genetic test result access and genetic discrimination.
